Viridian Therapeutics, Inc.\DE

Viridian Therapeutics is a biotechnology company focused on discovering and developing treatments for serious and rare diseases. The company's primary pipeline centers on monoclonal antibody therapies targeting the insulin-like growth factor-1 receptor (IGF-1R). Its lead candidate, veligrotug, is in Phase 3 clinical development for thyroid eye disease (TED), with a second-generation IGF-1R antibody, VRDN-003, also in Phase 3 trials for the same indication. The company is leveraging half-life extension technology to optimize its therapeutic candidates. Beyond IGF-1R programs, Viridian is developing a portfolio of engineered anti-neonatal Fc receptor inhibitors, including VRDN-006 and VRDN-008, for autoimmune disease applications.

The company operates as a clinical-stage biotechnology enterprise with 143 full-time employees and is headquartered in Waltham, Massachusetts. Viridian was founded in 2010 and was previously known as Miragen Therapeutics before changing its name in January 2021. The company is publicly traded on the Nasdaq under the ticker VRDN, with a market capitalization of approximately $2.8 billion as of the data provided.